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AbstrAct
We conducted a systematic review and meta-analysis to 
determine the effectiveness of healthcare provider-led 
(HCPs) interventions to support medication adherence in 
patients with acute coronary syndrome (ACS). A systematic 
search of Cochrane Library, Medline, EMBASE, PsycINFO, 
Web of Science, IPA, CINAHL, ASSIA, OpenGrey, EthOS, 
WorldCat and PQDT was undertaken. Interventions were 
deemed eligible if they included adult ACS patients, 
were HCP-led, measured medication adherence and 
randomised participants to parallel groups. Intervention 
content was coded using the Behaviour Change Technique 
(BCT) Taxonomy and data were pooled for analysis using 
random-effects models. Our search identified 8870 
records, of which 27 were eligible (23 primary studies). A 
meta-analysis (n=9735) revealed HCP-led interventions 
increased the odds of medication adherence by 54% 
compared to control interventions (k=23, OR 1.54, 95% CI 
1.26 to 1.88, I2=57.5%). After removing outliers, there was 
a 41% increase in the odds of medication adherence with 
moderate heterogeneity (k=21, OR 1.41, 95% CI 1.21 to 
1.65, I2=35.3%). Interventions that included phone contact 
yielded (k=12, OR 1.63, 95% CI 1.25 to 2.12, I2=32.0%) 
a larger effect compared to those delivered exclusively 
in person. A total of 32/93 BCTs were identified across 
interventions (mean=4.7, SD=2.2) with ‘information about 
health consequences’ (BCT 5.1) (19/23) the most common. 
HCP-led interventions for ACS patients appear to have a 
small positive impact on medication adherence. While we 
were able to identify BCTs among interventions, data were 
insufficient to determine the impact of particular BCTs on 
study effectiveness.
PROSPERO registration number CRD42016037706.
IntROductIOn
Pharmacological therapy is a key component 
of secondary prevention following acute 
coronary syndrome (ACS). Despite the effec-
tiveness of such therapies, many patients do 
not follow their regimen as prescribed and 
are deemed non-adherent. It is estimated 
that approximately one-third of patients 
are non-adherent to cardiac medications 
following ACS.1 Non-adherence among 
cardiac patients presents a considerable 
clinical problem because of its association 
with poor outcomes that include mortality, 
morbidity and risk of rehospitalisation.2 
Adherence is complex in nature and is 
driven by a myriad of patient-related (eg, 
beliefs about treatment), healthcare provider 
(HCP)-related (eg, communication) and 
healthcare system-wide factors (eg, treat-
ment cost and access). A recent review of 
psychosocial factors found that depression 
and treatment beliefs were predictors of 
non-adherence following ACS.3 Identifying 
potentially modifiable factors is crucial for 
the design and implementation of evidence-
based interventions to improve adherence.
There have been multiple attempts to 
synthesis the evidence base for adherence 
interventions in chronic disease,4 coro-
nary artery disease (CAD)5 and cardiovas-
cular disease.6 Moreover, there have been 
numerous reviews looking at interventions 
targeting adherence to specific medication 
classes including statins,7 antihypertensives8 
and oral antiplatelet therapy.9 HCPs (ie, physi-
cians, nurses, pharmacists) play a key role 
in supporting, promoting and monitoring 
adherence for chronic conditions. Previous 
reviews have reported the benefit of adher-
ence interventions delivered by multiple 
HCPs,10 pharmacists11 and nurses.5 However, 
to date, the impact of these types of inter-
ventions for patients with ACS has yet to be 
systematically explored.
Interventions that target behaviours such 
as medication taking are often complex and 
comprise multiple components. In order 
to identify the specific strategies best suited 
to change specific behaviours, complex 
interventions need to be compartmental-
ised. Behaviour change frameworks such 
as the theoretical domains framework12 
and behaviour change technique (BCT) 
taxonomy13 have been designed to aid this 
compartmentalisation process through speci-
fying interventions into their ‘active content’. 
These types of models have been used across 
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a range of health behaviours, and there is increasing 
application within medication adherence research.14
The primary objective of this systematic review and 
meta-analysis is to determine the effectiveness of HCP-led 
interventions to support medication adherence following 
ACS. Additionally, we aim to examine whether effective-
ness is moderated by interventionist, delivery method 
and having a theory-based design. Finally, we aim use a 
behaviour change framework to identify the specific tech-
niques used among adherence interventions.
MEthOdOlOgy
This review was conducted in accordance of the 
Preferred Reporting Items for Systematic reviews and 
Meta-Analysis guidelines15 and was registered with 
PROSPERO (http://www. crd. york. ac. uk/ PROSPERO/ 
display_ record. asp? ID= CRD42016037706).
Eligibility criteria
Studies were included if they met the following criteria:
1. Participants: adults (>18 years of age) with a confirmed 
diagnosis of ACS.
2. Intervention: delivered by HCPs.
3. Comparator: parallel group design where treatment 
group is compared with a clearly defined control 
group.
4. Outcome: include a measurement or medication ad-
herence as a primary or secondary outcome.
5. Setting: study group allocation determined by 
randomisation.
We defined an intervention as being HCP led if the 
primary method of delivery involved HCPs working 
therapeutically with patients in person and/or via 
phone.
Studies infrequently distinguish between the different 
types of non-adherence; therefore, we used a definition 
of medication adherence that includes treatment initia-
tion, actual dosing and treatment persistence.16
Search strategy
A systematic search of the following electronic data-
bases was conducted: The Cochrane Library, Medline, 
EMBASE, PsycINFO, Web of Science, International Phar-
maceutical Abstracts, Cumulative Index to Nursing and 
Allied Health Literature and Applied Social Sciences 
Index and Abstracts. An additional grey literature search 
was also undertaken: OpenGrey, EthOS, WorldCat—
Thesis and Dissertations and ProQuest Dissertations 
& Theses. Searches were limited to articles written in 
English with no timespan limits. Reference lists of rele-
vant papers were also searched to identify any additional 
records.
Our search strategy was informed by previous review 
studies4 5 and comprised four search themes: condition; 
therapy type; adherence; study design (see table 1) 
(for full search strategy, see online supplementary 
material 1).
data extraction
Records were imported into bibliographic software 
(EndNote X7) where duplicates were removed. All 
records were initially screened based on their title and 
abstract, and relevant articles were full-text screened using 
our eligibility criteria. All screening and data extraction 
was undertaken by a single researcher (JC) with expe-
rience conducting evidence syntheses. Two additional 
researchers (VA & JW) undertook partial screening using 
the eligibility criteria to validate the study selection and 
data extraction process. Any disagreements between 
raters (JC, VA and JW) were resolved by consensus. Data 
were extracted using a standardised data extraction form 
based on previous review studies4 5 17 (see table 2). Where 
necessary, study authors were contacted directly for addi-
tional information. We contacted 10 authors to clarify 
aspects of their methodology of which 80% responded.
Risk of bias
Methodological quality was judged using A Cochrane 
Risk of Bias Assessment Tool (ACROBAT)18 where risk 
is rated as ‘high’, ‘unclear’ or ‘low’ among six domains 
of bias (Selection; Performance; Detection; Attrition; 
Table 1 Search themes with example search terms
Search theme Examples of search terms
Condition Acute coronary syndrome, myocardial infarction, 
unstable angina, coronary occlusion, coronary 
thrombosis
Therapy type Treatment, medication, medicine, drug, 
pharmacotherapy, regimen, prescription, prescribed
Adherence Compliance, non-compliance, concordance, 
adherence, non-adherence, discordance, 
persistence, non-persistence, discontinuation, drop-
out, treatment refusal
Study design Random, clinical, control, trial, intervention, outcome, 
treatment outcome
Table 2 Data extraction criteria
Data category Specific extraction
Study details Author; title
Source attributes Study type; funding details; year of distribution
Methodological 
features
Group assignment; allocation concealment; 
comparator group; blinding; attrition; intention to 
treat; study period; outcome measurement
Participant 
characteristics
Age; gender; ethnicity; diagnosis
Intervention features Number of sessions; interventionist; length of 
delivery; theoretical basis; delivery method; 
targeting additional health behaviours
Intervention content BCTs
Effect size 
determinations
Sample size; methods of analysis; means; main 
effects
BCTs, behaviour change technique.
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Reporting and Other Biases). ACROBAT has been used 
in previous systematic reviews looking at the effectiveness 
of adherence interventions.19 Risk of bias was assessed by 
a single researcher (JC).
Statistical analysis
Medication adherence was our target outcome, and 
the direction of effect was transformed for consistent 
reporting. Where studies reported adherence across 
multiple medications the data were pooled to provide 
an estimate of ‘overall adherence’. Effect size estimates 
are expressed in terms of ORs. Where data were origi-
nally expressed as means, standardised mean differences 
were calculated and then transformed to the OR metric 
using the probit method.20 These should be interpreted 
as standardised OR.
Random-effects models comparing HCP-led interven-
tions with control interventions were used based on the 
assumption that there would be statistical heterogeneity 
from pooling primary study data. The I2 statistic was used 
to estimate statistical heterogeneity, and Cochrane guide-
lines were used for interpretation.21 Potential publication 
bias was determined using funnel plots and Egger’s test 
for small study effects. A critical value of. 1 was used for 
heterogeneity and small study effects significance testing. 
A study was deemed to be an outlier where the effect size 
was outside the pseudo 95% CI in the funnel plot as a 
means for detecting the potential impact of outliers on 
the pooled effect size.
Secondary studies (ie, primary study data with alter-
nate end-points) were excluded from meta-analysis so 
as not to duplicate data. Prespecified subgroup analyses 
were conducted based on (1) type of interventionist, 
(2) delivery method and (3) theory-based design. Addi-
tional post hoc analyses were done based on adherence 
outcome and risk of bias. All analyses were done using 
Stata 14.1.
coding intervention content
We used the BCT taxonomy13 to identify specific tech-
niques used to change medication-taking behaviour 
among our intervention studies. The BCT taxonomy 
comprises 93 unique BCTs categorised into 16 clusters. 
A BCT is defined as an ‘active ingredient’ that can be 
used to alter or redirect behaviour. The BCT taxonomy 
includes a detailed description of each technique and 
provides specific examples (eg, ‘action planning’ (BCT 
1.4): ‘prompt planning the performance of a particular physical 
activity at a particular time on certain days of the week’ (the 
numbers in parentheses refer to the BCT’s taxonomy 
cluster)). The BCT taxonomy has been used to code the 
content of interventions across a range of health behav-
iours including medication adherence.14
The BCT content of each intervention was rated by two 
researchers (JC and LA). Intervention data were sourced 
from each published manuscript and relevant supporting 
documents (ie, study protocols, intervention manuals). 
The researchers initially rated the interventions 
independently and then met to discuss. BCT content was 
scrutinised until consensus was met between researchers.
RESultS
Selection process
Our comprehensive search strategy identified 6072 
records that were initially screened based on their title 
and abstract (see figure 1). A total of 5874 records were 
excluded, leaving 198 records to be full-text screened. 
Twenty-seven studies22–48 met our eligibility criteria, 
which comprised 23 primary studies (4 secondary 
studies37 38 43 47) (for full reason for exclusion list, see 
online supplementary material). Only primary study data 
(k=23, n=9735) will be discussed in the following sections.
Study characteristics
Full details of the included studies can be found in 
table 3. The majority of interventions included nurses in 
their delivery (k=1323 24 26–28 31 33 35 36 40 42 45 48). Six inter-
ventions were led by pharmacists (k=622 29 30 32 41 48), and 
two were delivered by physicians (k=225 39). Physiother-
apists,44 problem-solving therapists34 and community 
health workers46 acted as interventionists in singular 
trials. Nine studies were delivered exclusively in person 
(k=924 26 27 31 34 36 39 41 48), while 10 studies included both 
in person and phone contact (k=1022 23 29 30 32 33 42 44–46). 
Just four study interventions were delivered exclusively 
by phone (k=425 28 35 40), while six included a face-to-face 
predischarge component (k=622 23 28 30 39 41). The number 
of intervention sessions ranged from 128 32 48 to 2426 (k=21; 
median=4.0, SD=6.0). A total of 10 studies followed 
patients up for either 6 (k=522 24 32 34 39) or 12 months 
(k=529–31 46 48) (k=23; median=6.0 months, SD=10.3 
months). Adherence to medication was a primary 
outcome in 14 studies (k=1422 24 28–30 32 34 36 39–42 45 46) and 
was measured exclusively by self-report in 16 studies 
(k=1623–28 31–34 36 39–41 44 45). Five studies used pharmacy 
data or pill counts (k=530 35 42 46 48), and just two studies 
used both self-report and pharmacy data to measure 
adherence (k=222 29).
Risk of bias
A summary of the risk of bias assessment can be seen in 
figure 2. All but one of the studies31 were rated as having 
‘unclear’ risk of performance bias due to the impracti-
cality of blinding participants and personnel to group 
allocation during behavioural studies. ‘High’ risk of 
detection bias was judged in nine studies that did not 
adopt end-point blinding (k=924 26 28 36 39 40 44 45 48). After 
excluding performance bias ratings, six studies were 
judged to have ‘low’ risk of bias across all other domains 
(k=622 27 30 34 41 44). Three of these ‘low-risk’ studies were 
delivered by pharmacists (k=322 30 41), and the rest were 
led by nurses,27 physiotherapists44 or problem-solving 
therapists.34 Trials with the smallest41 and largest sample 
sizes27 were among the ‘low risk’-rated studies, and all six 
were either delivered exclusively in person (k=327 34 41) or 
in person with phone contact (k=322 30 44) (for complete 
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risk of bias assessment, see online supplementary 
material).
Bct inclusion
Figure 3 shows the frequency of BCTs coded across studies. 
None of the studies referenced the BCT taxonomy in 
their intervention design. A total of 32 (34%) of the 
93 BCTs listed in the taxonomy were identified among 
studies, ranging between 128 33 and 1044 (mean=4.7, 
SD=2.2). ‘Information about health consequences’ (BCT 
5.1) was the most commonly identified BCT, coded in 19 
of the 23 studies. ‘Social support (unspecified)’ (BCT 
3.1) was coded in seven studies, and ‘action planning’ 
(BCT 1.4) was identified in just two studies.32 44 There 
were six instances of ‘goal setting (outcome)’ (BCT 1.3), 
‘monitoring of behaviour by others without feedback’ 
(BCT 2.1), ‘feedback on outcome(s) of behaviour’ (BCT 
2.7) and ‘instruction on how to perform the behaviour’ 
(BCT 4.1) across studies. Around two-thirds (67%) of 
the total number of BCTs coded were from just three 
taxonomy clusters: goals and planning (cluster 1, n=26 
(24%)), natural consequences (cluster 5, n=25 (23%)) 
and feedback and monitoring (cluster 2, n=21 (20%)). 
There were no BCTs coded from three taxonomy clus-
ters: reward and threat (cluster 10), scheduled conse-
quences (cluster 14) and covert learning (cluster 16). 
There were no instances where every BCT in a cluster was 
coded (goals and planning: cluster 1, 8/9 BCTs coded; 
feedback and monitoring: cluster 2, 6/7 BCTs coded). 
Meta-analysis
A random-effects meta-analysis of 23 primary studies 
(n=9735) revealed that HCP-led interventions increased 
the odds of medication adherence by 54% compared 
with control interventions with moderate to high statis-
tical heterogeneity (k=23, OR 1.54, 95% CI 1.26 to 1.88 
(I2=57.5%, P=0.001)) (see figure 4). After removing two 
outliers,40 45 a meta-analysis of 9545 patients indicated that 
HCP-led interventions increased the odds of medication 
adherence by 41% compared with control interventions 
with moderate statistical heterogeneity (k=21, OR 1.41, 
95% CI 1.21 to 1.65 (I2=35.3%, P=0.057)) (see figure 5). 
While Egger’s test was non-significant (P=0.286), visual 
inspection of the funnel plot suggests a potential bias 
even after discounting outliers (for funnel plot, see 
online supplementary material).
Subgroup analyses
Table 4 shows the results of our prespecified (ie, interven-
tionist, delivery method, theoretical basis) and post hoc 
(ie, adherence outcome, risk of bias) subgroup anal-
yses. The largest effect sizes were for interventions that 
Figure 1 Preferred Reporting Items for Systematic reviews and Meta-Analysis flow diagram showing the study selection 
process. ACS, acute coronary syndrome; ASSIA, Applied Social Sciences Index and Abstracts; CINAHL, Cumulative Index to 
Nursing and Allied Health Literature; HCP, healthcare provider; PQDT, ProQuest Dissertations & Theses.
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included phone contact (k=12, OR 1.63, 95% CI 1.25 to 
2.12), and there was a trend for better-quality studies (ie, 
‘low’ risk of bias) to increase the odds of adherence (k=6, 
OR 1.69, 95% CI 1.15 to 2.47). A negligible positive effect 
was found for interventions delivered by nurses (k=11, OR 
1.19, 95% CI 1.04 to 1.36), and pharmacist-led interven-
tions had a small though non-significant effect on medi-
cation adherence (k=6, OR 1.44, 95% CI 0.92 to 2.26). 
Studies led by HCPs other than nurses and pharmacists 
(ie, physicians,25 39 physiotherapists,44 problem-solving 
therapists,34 community health workers46) yielded a small 
positive effect on medication adherence (k=5, OR 1.66, 
95% CI 1.22 to 2.24). We found no discernible differences 
in effect size between studies that included adherence as 
a primary or secondary outcome, and a small number 
of theoretically informed studies had a non-significant 
trend towards a negative effect on adherence (k=4, OR 
0.94, 95% CI 0.60 to 1.49).
dIScuSSIOn
The primary objective of this study was to identify inter-
ventions led by HCPs to improve medication adherence 
following ACS. Meta-analysis revealed a small effect of 
HCP-led interventions on medication adherence. Our 
results are consistent with previous meta-analysis studies 
that have looked at the effectiveness of adherence inter-
ventions in other cardiac patient populations.5 17
In line with recent adherence literature,49 the 
majority of intervention studies identified were deliv-
ered by nurses or pharmacists. However, we found no 
indication that study effectiveness was moderated by the 
HCP delivering the intervention. Studies that included 
nurses in their delivery had a negligible effect towards 
better medication adherence, which does not corre-
spond to findings from another meta-analysis that found 
that nurse-led interventions had a small to medium 
effect on adherence in patients with CAD.5 Six phar-
macist-led interventions had a small but non-significant 
effect on medication adherence, which is congruous 
with previous reviews across cardiac-related diseases.5 17 
Objectively, pharmacists should be ideal candidates to 
deliver adherence interventions due to the necessary 
knowledge and skills they possess to promote and 
support medication-taking behaviour.50 A meta-analysis 
of 771 medication adherence intervention trials found 
that the most effective interventions were delivered by 
pharmacists,49 which suggests that pharmacists may be 
better utilsied in other patient populations. Our find-
ings should, however, be interpreted with caution due 
to the small number of pharmacist-led studies included 
in our analyses.
In terms of delivery method, interventions that included 
phone contact had higher odds of medication adher-
ence compared with interventions delivered exclusively 
in person. Phone-delivered interventions may be a more 
convenient method to reach patients after discharge to 
monitor and encourage good medication adherence 
over time. Half of the interventions that included phone 
contact also contained a face-to-face predischarge compo-
nent. Cutrona et al51 found that two-thirds of interven-
tions delivered at discharge were effective at improving 
adherence to cardiovascular medicines. Periods of care 
transition such as during hospital discharge are ideal 
opportunities to discuss treatment to pre-empt poten-
tial barriers to regimen adherence. Moreover, the 
dynamic nature of adherence dictates that monitoring of 
Figure 2 Risk of bias assessment.
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medication-taking behaviour over time by both patients 
and/or HCPs is crucial to ensure therapy maintenance 
for long-term conditions such as ACS.
We expected to find a greater proportion of inter-
ventions that used theoretical approaches to change 
medication-taking behaviour. There were only four 
studies that reported a theoretical basis, of which just one 
was based on a model of medication-taking behaviour 
(necessity–concerns framework52). A review by Conn 
et al53 found that theory-driven interventions had a 
Figure 3 Frequency of BCTs identified among interventions. BCT, behaviour change technique.
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significant but modest effect on medication adherence. 
Our findings suggest that theory-driven adherence 
interventions for ACS are lacking, thus highlighting an 
important avenue for future research.
coding intervention content
To our knowledge, this review is the first to use the BCT 
taxonomy to code interventions that targeted adherence 
across all cardiac medications following ACS. The BCT 
taxonomy provided a useful tool to analyse the content 
of adherence interventions, and we found that one-third 
of all BCTs detailed in the taxonomy were identified in 
at least one intervention. This relatively small number of 
total BCTs identified was unsurprising as many were not 
applicable to medication-taking behaviour. It is likely that 
additional strategies may have been used among inter-
ventions but were not identified due to a lack of detail 
in the description of the intervention. A lack of transpar-
ency in study reporting is an issue that limits the usability 
and replicability of interventional research. Checklists 
such as TIDieR54 are becoming commonplace to improve 
the quality of intervention reporting.
Written, verbal or visual information provision about 
the consequences of adherence (BCT 5.1) was by far 
the most frequently used BCT among HCP-led interven-
tions. Discussing the consequences of non-adherence 
may help to strengthen patients’ beliefs in the necessity 
of their medications, which have been shown to predict 
non-adherence.55 While information is necessary to 
improve patients’ knowledge, it is not sufficient as a stand-
alone strategy to change behaviour. Information-only 
strategies have been found to be generally ineffective at 
changing complex behaviours such as adherence.56
clinical and research implications
Medication taking is a complex behaviour that can be 
difficult to change. Targeting patients identified with an 
adherence issue rather than all medication-takers may be 
one strategy to improve the effectiveness of adherence 
interventions. Cutrona et al57 reported that ‘broad’ inter-
ventions (target all medication-takers) were less effective 
than ‘focused’ (target non-adherers only). None of the 
studies identified in this review targeted non-adherers; 
therefore, it is not yet known whether ‘focused’ interven-
tions would be more appropriate for patients with ACS.
There were a variety of adherence measures used 
among included interventions, most of which were 
non-validated self-report tools. While an approach that 
combines self-reporting with an objective measure (eg, 
prescription refill records) is considered best prac-
tice, just two interventions followed this guidance. 
No studies used electronic monitors (eg, Medication 
Event Monitoring System) that provide real-time data 
on medication-taking behaviour58 and have been used 
to good effect in studies with patients with hyperten-
sion,59 heart failure60 and CAD.61 There is potential 
Figure 4 Forest plot showing pooled effects size for healthcare-provider-led interventions on medication adherence 
(k=23, includes outliers).
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for objective measures to be used in conjunction with 
self-report tools to provide a more reliable and accu-
rate representation of medication-taking behaviour 
of patients with ACS.
Strengths and limitations
The strengths of this study include the adoption of a 
comprehensive search strategy that comprised eight 
online databases and a supplementary grey literature 
search. Additionally, we applied an existing behav-
iour change framework to identify specific techniques 
used among HCP-led adherence interventions, which 
we believe is a novel approach for trials with patients 
with ACS. Our study does also include certain limi-
tations. First, while we were successful in BCT iden-
tification, there were insufficient data to determine 
the effectiveness of particular BCTs. A larger data set 
would be required to undertake the type of meta-re-
gression analyses that have recently been reported 
within the adherence literature.62 Second, we found 
relatively high levels of statistical heterogeneity in 
our random-effects models, which is inherent when 
comparing methodologically diverse behavioural 
interventions. We accounted for this variability by 
removing outliers, which resulted in our final model 
having moderate statistical heterogeneity. Third, only 
one researcher was involved in all aspects of the iden-
tification, screening, data extraction and risk of bias 
assessments, although dual-raters coded interventions 
independently using the BCT taxonomy. Best practice 
would be to include multiple independent raters in all 
stages of the review to ensure methodological rigour. 
Fourth, we decided not to exclude studies based 
on how medication adherence was measured, which 
was often done using unreliable self-report methods. 
A previous review by Santo et al63 circumvented this 
issue somewhat by including stricter adherence meas-
urement eligibility criteria. Ultimately, all methods of 
adherence measurement are limited in terms of prac-
ticality, reliability and cost, which represents a wider 
issue across the adherence literature.
cOncluSIOn
This study suggests that HCP-led interventions have a 
small positive effect on medication adherence following 
ACS. An existing BCT taxonomy was used successfully 
to identify common techniques within adherence inter-
ventions. However, data were insufficient to draw firm 
conclusions regarding the impact of BCTs on intervention 
Figure 5 Forest plot showing pooled effects size for healthcare-provider-led interventions on medication adherence (k=21, 
outliers removed).
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effectiveness. Information provision remains the basis of 
most adherence interventions. Further work is required 
to understand how intervention design and delivery 
determines the effectiveness of adherence interventions 
following ACS.
contributors Concept design was undertaken by JC, VA and JW. JC undertook 
the literature search with VA and JW involved in eligibility screening. LA and 
SN contributed to behaviour change technique coding and statistical analyses, 
respectively. JC wrote the first draft, with all authors contributing to the critical 
revision of the manuscript. 
Funding The authors report that this study was supported by a King’s College 
London-University of California, San Francisco PhD Studentship (for JC). 
competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work 
is properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent 
cardiovascular disease: meta-analysis on 376,162 patients. Am J 
Med 2012;125:882–7.
 2. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is 
associated with a broad range of adverse outcomes in patients with 
coronary artery disease. Am Heart J 2008;155:772–9.
 3. Crawshaw J, Auyeung V, Norton S, et al. Identifying psychosocial 
predictors of medication non-adherence following acute coronary 
syndrome: A systematic review and meta-analysis. J Psychosom 
Res 2016;90:10–32.
 4. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for 
enhancing medication adherence. Cochrane Database Syst Rev 
2014:CD000011.
 5. Chase JA, Bogener JL, Ruppar TM, et al. The effectiveness of 
medication adherence interventions among patients with coronary 
artery disease: a meta-analysis. J Cardiovasc Nurs 2016;31:357–66.
 6. Laba TL, Bleasel J, Brien JA, et al. Strategies to improve adherence 
to medications for cardiovascular diseases in socioeconomically 
disadvantaged populations: a systematic review. Int J Cardiol 
2013;167:2430–40.
 7. Jörntén-Karlsson M, Pintat S, Molloy-Bland M, et al. Patient-
centered interventions to improve adherence to statins: a 
narrative synthesis of systematically identified studies. Drugs 
2016;76:1447–65.
 8. Takiya LN, Peterson AM, Finley RS. Meta-analysis of interventions 
for medication adherence to antihypertensives. Ann Pharmacother 
2004;38:1617–24.
 9. Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet 
treatment with P2Y12 receptor inhibitors. is there anything we can 
do to improve it? A systematic review of randomized trials. Curr Med 
Res Opin 2016;32:1441–51.
Table 4 Overall effects and subgroup analyses for medication adherence interventions
k N OR CI I² (%) P heterogeneity P bias
Overall
  All studies 23 9735 1.54 1.26 to 1.88 57.5 0.001 0.066
  Excluding outliers 21 9545 1.41 1.21 to 1.65 35.3 0.057 0.286
Interventionist
  Pharmacist 6 813 1.44 0.92 to 2.26 30.0 0.210 0.309
  No pharmacist 15 8732 1.41 1.19 to 1.68 41.0 0.049 0.439
  Nurse 11 5030 1.19 1.04 to 1.36 0 0.920 0.501
  No nurse 10 4515 1.63 1.26 to 2.10 52.1 0.027 0.454
  Other HCPs 5 3842 1.66 1.22 to 2.24 67.1 0.012 0.550
  Nurse or pharmacists 16 5703 1.21 1.07 to 1.38 0 0.663 0.167
Delivery method
  In person only 9 6358 1.21 1.08 to 1.36 0 0.890 0.305
  Included phone contact 12 3187 1.63 1.25 to 2.12 32.0 0.135 0.629
Theoretical basis
  Theory based 4 686 0.94 0.60 to 1.49 0 0.781 0.692
  Not theory based 17 8859 1.48 1.25 to 1.76 41.4 0.038 0.094
Outcome
  Primary 12 3833 1.31 1.11 to 1.54 0 0.622 0.227
  Secondary 9 5712 1.48 1.12 to 1.96 63.1 0.006 0.548
Risk of bias
  Low risk 6 3948 1.69 1.15 to 2.47 51.4 0.068 0.042
  Higher risk 15 5597 1.36 1.13 to 1.64 28.1 0.147 0.658
HCP, healthcare provider; I²,  heterogeneity; k, number of studies; N, sample size; P  bias,  small study effects significance; P 
heterogeneity, heterogeneity significance.
Interventionist, delivery method and theoretical basis were prespecified subgroups, while outcome and risk of bias were determined 
post hoc. Outliers were excluded from subgroup analyses.40 45
Trust. Protected by copyright.
 o
n
 O
ctober 25, 2019 at G
uy's & St Thom
as' Hospitals NHS
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2017-000685 on 22 Decem
ber 2017. Downloaded from
 
Open Heart
16 Crawshaw J, et al. Open Heart 2017;4:e000685. doi:10.1136/openhrt-2017-000685
 10. Mansoor SM, Krass I, Aslani P. Multiprofessional interventions to 
improve patient adherence to cardiovascular medications.  
J Cardiovasc Pharmacol Ther 2013;18:19–30.
 11. Jalal ZS, Smith F, Taylor D, et al. Pharmacy care and adherence 
to primary and secondary prevention cardiovascular medication: 
a systematic review of studies. Eur J Hosp Pharm Sci Pract 
2014;21:238–44.
 12. Michie S, Johnston M, Abraham C, et al. Making psychological 
theory useful for implementing evidence based practice: a 
consensus approach. Qual Saf Health Care 2005;14:26–33.
 13. Michie S, Richardson M, Johnston M, et al. The behavior change 
technique taxonomy (v1) of 93 hierarchically clustered techniques: 
building an international consensus for the reporting of behavior 
change interventions. Ann Behav Med 2013;46:81–95.
 14. Johnston N, Weinman J, Ashworth L, et al. Systematic 
reviews: causes of non-adherence to P2Y12 inhibitors in acute 
coronary syndromes and response to intervention. Open Heart 
2016;3:e000479.
 15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for 
reporting systematic reviews and meta-analyses of studies that 
evaluate healthcare interventions: explanation and elaboration. BMJ 
2009;339:b2700.
 16. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for 
describing and defining adherence to medications. Br J Clin 
Pharmacol 2012;73:691–705.
 17. Conn VS, Ruppar TM, Chase JA, et al. Interventions to improve 
medication adherence in hypertensive patients: systematic review 
and meta-analysis. Curr Hypertens Rep 2015;17:94.
 18. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials. 
BMJ 2011;343:d5928.
 19. Goodwin L, Ostuzzi G, Khan N, et al. Can we identify the active 
ingredients of behaviour change interventions for coronary heart 
disease patients? A systematic review and meta-analysis. PLoS One 
2016;11:e0153271.
 20. Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks, CA: 
Sage publications, 2001.
 21. Higgins J, Green S. Cochrane handbook for systematic reviews of 
interventions: John Wiley & Sons, 2011.
 22. Calvert SB, Kramer JM, Anstrom KJ, et al. Patient-focused 
intervention to improve long-term adherence to evidence-based 
medications: a randomized trial. Am Heart J 2012;163:657–65.
 23. Cossette S, Frasure-Smith N, Dupuis J, et al. Randomized controlled 
trial of tailored nursing interventions to improve cardiac rehabilitation 
enrollment. Nurs Res 2012;61:111–20.
 24. Costa e Silva R, Pellanda L, Portal V, et al. Transdisciplinary 
approach to the follow-up of patients after myocardial infarction. 
Clinics 2008;63:489-96.
 25. Du L, Dong P, Jia J, et al. Impacts of intensive follow-up on the 
long-term prognosis of percutaneous coronary intervention in 
acute coronary syndrome patients - a single center prospective 
randomized controlled study in a Chinese population. Eur J Prev 
Cardiol 2016;23:1077–85.
 26. Giallauria F, Lucci R, D'Agostino M, et al. Two-year 
multicomprehensive secondary prevention program: favorable 
effects on cardiovascular functional capacity and coronary 
risk profile after acute myocardial infarction. J Cardiovasc Med 
2009;10:772–80.
 27. Giannuzzi P, Temporelli PL, Marchioli R, et al. Global secondary 
prevention strategies to limit event recurrence after myocardial 
infarction: results of the GOSPEL study, a multicenter, randomized 
controlled trial from the Italian cardiac rehabilitation network. Arch 
Intern Med 2008;168:2194–204.
 28. Gould KA. A randomized controlled trial of a discharge nursing 
intervention to promote self-regulation of care for early discharge 
interventional cardiology patients. Dimens Crit Care Nurs 
2011;30:117–25.
 29. Gujral G, Winckel K, Nissen LM, et al. Impact of community 
pharmacist intervention discussing patients’ beliefs to improve 
medication adherence. Int J Clin Pharm 2014;36:1048–58.
 30. Ho PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention 
to improve medication adherence and secondary prevention 
measures after acute coronary syndrome hospital discharge: a 
randomized clinical trial. JAMA Intern Med 2014;174:186–93.
 31. Jorstad HT, von Birgelen C, Alings AM, et al. Effect of a nurse-
coordinated prevention programme on cardiovascular risk after 
an acute coronary syndrome: main results of the RESPONSE 
randomised trial. Heart 2013;99:1421–30.
 32. M A Jalal ZS, Smith F, Taylor D, et al. Impact of pharmacy care upon 
adherence to cardiovascular medicines: a feasibility pilot controlled 
trial. Eur J Hosp Pharm Sci Pract 2016;23:250–6.
 33. Kotowycz MA, Cosman TL, Tartaglia C, et al. Safety and feasibility 
of early hospital discharge in ST-segment elevation myocardial 
infarction-A prospective and randomized trial in low-risk primary 
percutaneous coronary intervention patients (the safe-depart trial). 
Am Heart J 2010;159:117.
 34. Kronish IM, Rieckmann N, Burg MM, et al. The effect of enhanced 
depression care on adherence to risk-reducing behaviors after acute 
coronary syndromes: findings from the COPES trial. Am Heart J 
2012;164:524–9.
 35. Lapointe F, Lepage S, Larrivée L, et al. Surveillance and treatment of 
dyslipidemia in the post-infarct patient: can a nurse-led management 
approach make a difference? Can J Cardiol 2006;22:761–7.
 36. Miller P, Wikoff R, McMahon M, et al. Influence of a nursing 
intervention on regimen adherence and societal adjustments 
postmyocardial infarction. Nurs Res 1988;37:297–302.
 37. Miller P, Wikoff R, McMahon M, et al. Personal adjustments and 
regimen compliance 1 year after myocardial infarction. Heart Lung 
1989;18:339–46.
 38. Miller P, Wikoff R, Garrett MJ, et al. Regimen compliance two years 
after myocardial infarction. Nurs Res 1990;39:333–6.
 39. Muñiz J, Gómez-Doblas JJ, Santiago-Pérez MI, et al. The effect of 
post-discharge educational intervention on patients in achieving 
objectives in modifiable risk factors six months after discharge 
following an episode of acute coronary syndrome, (CAM-2 
Project): a randomized controlled trial. Health Qual Life Outcomes 
2010;8:137.
 40. Najafi SS, Shaabani M, Momennassab M, et al. The nurse-led 
telephone follow-up on medication and dietary adherence among 
patients after myocardial infarction: a randomized controlled clinical 
trial. Int J Community Based Nurs Midwifery 2016;4:199.
 41. Polack J, Jorgenson D, Robertson P. Evaluation of different 
methods of providing medication-related education to patients 
following myocardial infarction. Canadian Pharmacists Journal 
2008;141:241–7.
 42. Polsook R, Aungsuroch Y, Thongvichean T. The effect of self-efficacy 
enhancement program on medication adherence among post-acute 
myocardial infarction. Appl Nurs Res 2016;32:67–72.
 43. Redfern J, Briffa T, Ellis E, et al. Choice of secondary prevention 
improves risk factors after acute coronary syndrome: 1-year 
follow-up of the CHOICE (Choice of Health Options In prevention 
of Cardiovascular Events) randomised controlled trial. Heart 
2009;95:468–75.
 44. Redfern J, Briffa T, Ellis E, et al. Patient-centered modular secondary 
prevention following acute coronary syndrome: a randomized 
controlled trial. J Cardiopulm Rehabil Prev 2008;28:107–15.
 45. Uysal H, Ozcan Ş. The effect of individual education on patients’ 
physical activity capacity after myocardial infarction. Int J Nurs Pract 
2015;21:18–28.
 46. Xavier D, Gupta R, Kamath D, et al. Community health worker-based 
intervention for adherence to drugs and lifestyle change after acute 
coronary syndrome: a multicentre, open, randomised controlled trial. 
Lancet Diabetes Endocrinol 2016;4:244–53.
 47. Sharma KK, Gupta R, Mathur M, et al. Non-physician health workers 
for improving adherence to medications and healthy lifestyle 
following acute coronary syndrome: 24-month follow-up study. 
Indian Heart J 2016;68:832–40.
 48. Yorio J, Viswanathan S, See R, et al. The effect of a disease 
management algorithm and dedicated postacute coronary syndrome 
clinic on achievement of guideline compliance. J Investig Med 
2008;56:15–25.
 49. Conn VS, Ruppar TM. Medication adherence outcomes of 771 
intervention trials: systematic review and meta-analysis. Prev Med 
2017;99:269–76.
 50. Carter P. Operational productivity and performance in English NHS 
acute hospitals: unwarranted variations. an independent report for 
the department of health by lord carter of coles. London: Department 
of Health, 2016.
 51. Cutrona SL, Choudhry NK, Fischer MA, et al. Modes of delivery for 
interventions to improve cardiovascular medication adherence. Am J 
Manag Care 2010;16:929.
 52. Horne R, Weinman J. Patients’ beliefs about prescribed medicines 
and their role in adherence to treatment in chronic physical illness.  
J Psychosom Res 1999;47:555–67.
 53. Conn VS, Enriquez M, Ruppar TM, et al. Meta-analyses of theory use 
in medication adherence intervention research. Am J Health Behav 
2016;40:155–71.
 54. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of 
interventions: template for intervention description and replication 
(TIDieR) checklist and guide. BMJ 2014;348:g1687.
 55. Horne R, Chapman SC, Parham R, et al. Understanding patients’ 
adherence-related beliefs about medicines prescribed for long-
Trust. Protected by copyright.
 o
n
 O
ctober 25, 2019 at G
uy's & St Thom
as' Hospitals NHS
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2017-000685 on 22 Decem
ber 2017. Downloaded from
 
17Crawshaw J, et al. Open Heart 2017;4:e000685. doi:10.1136/openhrt-2017-000685
Review
term conditions: a meta-analytic review of the necessity-concerns 
framework. PLoS One 2013;8:e80633.
 56. van Dulmen S, Sluijs E, van Dijk L, et al. Patient adherence to 
medical treatment: a review of reviews. BMC Health Serv Res 
2007;7:55.
 57. Cutrona SL, Choudhry NK, Fischer MA, et al. Targeting 
cardiovascular medication adherence interventions. J Am Pharm 
Assoc 2012;52:381–97.
 58. El Alili M, Vrijens B, Demonceau J, et al. A scoping review of studies 
comparing the medication event monitoring system (MEMS) with 
alternative methods for measuring medication adherence. Br J Clin 
Pharmacol 2016;82:268–79.
 59. Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, et al. Efficacy 
of a home blood pressure monitoring programme on therapeutic 
compliance in hypertension: the EAPACUM-HTA study. J Hypertens 
2006;24:169–75.
 60. Murray MD, Young J, Hoke S, et al. Pharmacist intervention to 
improve medication adherence in heart failure: a randomized trial. 
Ann Intern Med 2007;146:714–25.
 61. Park LG, Howie-Esquivel J, Chung ML, et al. A text messaging 
intervention to promote medication adherence for patients with 
coronary heart disease: a randomized controlled trial. Patient Educ 
Couns 2014;94:261–8.
 62. Kassavou A, Sutton S. Automated telecommunication interventions 
to promote adherence to cardio-metabolic medications: meta-
analysis of effectiveness and meta-regression of behaviour change 
techniques. Health Psychol Rev 2017:1–18.
 63. Santo K, Kirkendall S, Laba TL, et al. Interventions to improve 
medication adherence in coronary disease patients: a systematic 
review and meta-analysis of randomised controlled trials. Eur J Prev 
Cardiol 2016;23:1065–76.
Trust. Protected by copyright.
 o
n
 O
ctober 25, 2019 at G
uy's & St Thom
as' Hospitals NHS
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2017-000685 on 22 Decem
ber 2017. Downloaded from
 
